BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33863776)

  • 1. Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
    Chen L; Zhai Y; Wang Y; Fearon ER; Núñez G; Inohara N; Cho KR
    Cancer Res; 2021 Jun; 81(12):3309-3318. PubMed ID: 33863776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
    Hou X; Zhai Y; Hu K; Liu CJ; Udager A; Pearce CL; Fearon ER; Cho KR
    Gynecol Oncol; 2022 Jun; 165(3):552-559. PubMed ID: 35414426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
    Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
    Zhai Y; Wu R; Kuick R; Sessine MS; Schulman S; Green M; Fearon ER; Cho KR
    J Pathol; 2017 Sep; 243(1):16-25. PubMed ID: 28608929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
    Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
    J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer.
    Paris EA; Bahr JM; Bitterman P; Basu S; Abramowicz JS; Barua A
    PLoS One; 2021; 16(7):e0255007. PubMed ID: 34314463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
    Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 9. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
    Huang D; Gaul DA; Nan H; Kim J; Fernández FM
    J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.
    Shi M; Whorton AE; Sekulovski N; Paquet M; MacLean JA; Song Y; Van Dyke T; Hayashi K
    Biol Reprod; 2020 Apr; 102(5):1055-1064. PubMed ID: 31930396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
    Zhang S; Iyer S; Ran H; Dolgalev I; Gu S; Wei W; Foster CJR; Loomis CA; Olvera N; Dao F; Levine DA; Weinberg RA; Neel BG
    Cancer Discov; 2021 Feb; 11(2):362-383. PubMed ID: 33158842
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
    Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study.
    Nené NR; Reisel D; Leimbach A; Franchi D; Jones A; Evans I; Knapp S; Ryan A; Ghazali S; Timms JF; Paprotka T; Bjørge L; Zikan M; Cibula D; Colombo N; Widschwendter M
    Lancet Oncol; 2019 Aug; 20(8):1171-1182. PubMed ID: 31300207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of gut microbiota manipulation with antibiotics on colon tumorigenesis in a murine model.
    Lee JG; Eun CS; Jo SV; Lee AR; Park CH; Han DS
    PLoS One; 2019; 14(12):e0226907. PubMed ID: 31860645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gut microbiome modulates colon tumorigenesis.
    Zackular JP; Baxter NT; Iverson KD; Sadler WD; Petrosino JF; Chen GY; Schloss PD
    mBio; 2013 Nov; 4(6):e00692-13. PubMed ID: 24194538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genistein Prevents Development of Spontaneous Ovarian Cancer and Inhibits Tumor Growth in Hen Model.
    Sahin K; Yenice E; Bilir B; Orhan C; Tuzcu M; Sahin N; Ozercan IH; Kabil N; Ozpolat B; Kucuk O
    Cancer Prev Res (Phila); 2019 Mar; 12(3):135-146. PubMed ID: 30651293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precious GEMMs: emergence of faithful models for ovarian cancer research.
    Stuckelberger S; Drapkin R
    J Pathol; 2018 Jun; 245(2):129-131. PubMed ID: 29493783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
    Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.